RHOA and benign prostatic hyperplasia: Therefore, PDE5Is could be used as pharmacological tools for the treatment of ED, LUTS/BPH and chronic pelvic ischemia by smooth muscle relaxation via cGMP-dependent RhoA/Rho-kinase (ROCK) signaling inhibition [105–108], and possibly by reducing autonomic hyperactivity, which is a component of the metabolic syndrome [109].